Home » Topics » BioWorld Science

BioWorld Science
RSS

ATIII in development at Genzyme Transgenics

April 12, 1996

Neutralase to enter phase II

April 12, 1996

YM-087 in phase I for CHF

April 12, 1996

New angiotensin II antagonists from Kotobuki

April 12, 1996

Sanofi Winthrop claims elastase inhibitors

April 12, 1996

Zafirlukast approval recommended

April 12, 1996

BDNF, CNTF protect against metabolic stress in vitro

April 12, 1996

New antiasthma drugs from the SmithKline Beecham Laboratory

April 12, 1996

Lubeluzole + DCLHb potentially effective in stroke

April 12, 1996

Hu23F2G advances to phase II

April 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.